Novo Nordisk Posts Higher Profit

Loading...
Loading...
Novo Nordisk A/S
NVO
reported upbeat profit for the fourth quarter. Novo Nordisk's quarterly net profit rose to 6.53 billion Danish kroner ($991 million), or DKK2.51 per share. Analysts were expecting a profit of DKK6.37 billion. Its revenue climbed 13% in Danish kroner to DKK24.59 billion versus DKK21.70 billion, while operating profit gained by 18% in local currencies and by 25% in Danish kroner. Novo Nordisk's gross margin narrowed to 83.7% from 84.3%. For the year, sales rose 8% in local currencies to 88.8 billion. Net profit gained 5% to DKK 26.5 billion, while diluted earnings per share rose 8% to DKK 10.07. Lars Rebien Sørensen, president and CEO: "We are pleased with Novo Nordisk's financial performance in 2014; a more challenging year than usual. Levemir® and Victoza® drove most of our sales growth, and our new long-acting insulin Tresiba® continues to perform well. 2015 will be an important year for us with the first launches of Saxenda® and Xultophy® as well as significant results from our late-stage development portfolio." The company projects 2015 sales growth of 6% to 9% in local currencies and a net financial loss of about DKK 5 billion. Novo Nordisk shares rose 2.09% to close at $45.92 yesterday.
Loading...
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsprofit
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...